In patients with Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML)

Prognostic value for your patients1,2

International Scale (IS) RQ-PCR testing is associated with clinically significant results1-3

  • IS RQ-PCR is preferred over cytogenetics to monitor response to TKI therapy4
    • FISH is not recommended to monitor response4
    • IS RQ-PCR can identify patients without early response and may be used to predict survival and guide subsequent therapy1

Early molecular response can be assessed using an IS-standardized RQ-PCR assay1,2,4

Early molecular response (≤10% IS BCR-ABL mRNA at 3 months) may predict long-term survival1

  • Patients who reach early molecular milestones are more likely to achieve and maintain deep molecular responses1
Early molecular response matters for Chronic Myeloid Leukemia Early molecular response matters for Chronic Myeloid Leukemia Early molecular response matters for Chronic Myeloid Leukemia
The National Comprehensive Cancer Network makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

RQ-PCR, real-time quantitative polymerase chain reaction; TKI, tyrosine kinase inhibitor; FISH, fluorescence in situ hybridization; mRNA, messenger ribonucleic acid; OS, overall survival.

References: 1. Marin D, Ibrahim AR, Lucas C, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol. 2012;30(3):232-238. 2. Savona MR. Molecular monitoring and minimal residual disease in the management of chronic myelogenous leukemia. J Community Support Oncol. 2014;12(5):171-178. 3. Hughes TP, Hochhaus A, Branford S, et al. Blood. 2010;116(19):3758-3765. 4. Referenced with permission from the NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) for Chronic Myeloid Leukemia V.2.2017. © National Comprehensive Cancer Network, Inc. 2017. All rights reserved. Accessed March 1, 2017. To view the most recent and complete version of the guideline, go online to NCCN.org.